Company news

Pfizer has received antitrust approval in its bid to purchase Encysive Pharmaceuticals for about $195 million. The company's offer to buy outstanding Encysive shares for $2.35 apiece expires at the end of March 31. The deal was announced last month.
Pfizer is looking to purchase Encysive to bolster is high blood pressure product portfolio.
You must be a registered member of MMM to post a comment.